TY - JOUR
T1 - Mpox Diagnosis, Behavioral Risk Modification, and Vaccination Uptake among Gay, Bisexual, and Other Men Who Have Sex with Men, United Kingdom, 2022
AU - UK Health Security Agency Sexual Health Liaison Group
AU - Ogaz, Dana
AU - Enayat, Qudsia
AU - Brown, Jack R.G.
AU - Phillips, Dawn
AU - Wilkie, Ruth
AU - Jayes, Danielle
AU - Reid, David
AU - Hughes, Gwenda
AU - Mercer, Catherine H.
AU - Saunders, John
AU - Mohammed, Hamish
N1 - Publisher Copyright:
© 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2024/5
Y1 - 2024/5
N2 - During the 2022 multicountry mpox outbreak, the United Kingdom identified cases beginning in May. UK cases increased in June, peaked in July, then rapidly declined after September 2022. Public health responses included community-supported messaging and targeted mpox vaccination among eligible gay, bisexual, and other men who have sex with men (GBMSM). Using data from an online survey of GBMSM during November–December 2022, we examined self-reported mpox diagnoses, behavioral risk modification, and mpox vaccination offer and uptake. Among 1,333 participants, only 35 (2.6%) ever tested mpox-positive, but 707 (53%) reported behavior modification to avoid mpox. Among vaccine-eligible GBMSM, uptake was 69% (95% CI 65%–72%; 601/875) and was 92% (95% CI 89%–94%; 601/655) among those offered vaccine. GBMSM self-identifying as bisexual, reporting lower educational qualifications, or identifying as unemployed were less likely to be vaccinated. Equitable offer and provision of mpox vaccine are needed to minimize the risk for future outbreaks and mpox-related health inequalities.
AB - During the 2022 multicountry mpox outbreak, the United Kingdom identified cases beginning in May. UK cases increased in June, peaked in July, then rapidly declined after September 2022. Public health responses included community-supported messaging and targeted mpox vaccination among eligible gay, bisexual, and other men who have sex with men (GBMSM). Using data from an online survey of GBMSM during November–December 2022, we examined self-reported mpox diagnoses, behavioral risk modification, and mpox vaccination offer and uptake. Among 1,333 participants, only 35 (2.6%) ever tested mpox-positive, but 707 (53%) reported behavior modification to avoid mpox. Among vaccine-eligible GBMSM, uptake was 69% (95% CI 65%–72%; 601/875) and was 92% (95% CI 89%–94%; 601/655) among those offered vaccine. GBMSM self-identifying as bisexual, reporting lower educational qualifications, or identifying as unemployed were less likely to be vaccinated. Equitable offer and provision of mpox vaccine are needed to minimize the risk for future outbreaks and mpox-related health inequalities.
UR - http://www.scopus.com/inward/record.url?scp=85191616189&partnerID=8YFLogxK
U2 - 10.3201/eid3005.230676
DO - 10.3201/eid3005.230676
M3 - Article
C2 - 38573160
AN - SCOPUS:85191616189
SN - 1080-6040
VL - 30
SP - 916
EP - 925
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 5
ER -
